Abbott Q3 2026: A Choppy Quarter, a Slower Libre, and a Nutrition Spin-Off
Abbott's Q3 2026 was in line on the numbers — sales of $13.0B, comparable growth of 7.0%, adjusted EPS of $1.42 — but the stock fell as management cut full-year comparable sales growth guidance to ~6% and guided diabetes care to low-to-mid single-digit growth for the next few quarters. Electrophysiology (+15%) and the Exact Sciences cancer diagnostics business (+14%) are carrying growth while Libre decelerates on international price pressure, with the Medicare type 2 coverage decision still a 2027 event. Adjusted margins expanded (gross margin 57.2%), the FY EPS guide held at $5.50-$5.55, and…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.